KIORA PHARMACEUTICALS INC — Director's Dealing 2018

Apr 17, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2018-04-13

Reporting Person: ARMISTICE CAPITAL, LLC (10% Owner)
Reporting Person: Armistice Capital Master Fund Ltd. (10% Owner)
Reporting Person: Boyd Steven (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-13	Common Stock	P	7425193	$0.3322	Acquired	10657723	Direct
2018-04-13	Common Stock	P	0	—	Acquired	10657723	Indirect
2018-04-13	Common Stock	P	0	—	Acquired	10657723	Indirect
2018-04-16	Common Stock	P	1159167	$0.3759	Acquired	11816890	Direct
2018-04-16	Common Stock	P	0	—	Acquired	11816890	Indirect
2018-04-16	Common Stock	P	0	—	Acquired	11816890	Indirect
2018-04-17	Common Stock	P	1895610	$0.4419	Acquired	13712500	Direct
2018-04-17	Common Stock	P	0	—	Acquired	13712500	Indirect
2018-04-17	Common Stock	P	0	—	Acquired	13712500	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-16	Warrants	$0.32	P	5468750	Acquired	2023-04-17	Common Stock (5468750)	Direct
2018-04-16	Warrants	$0.32	P	0	Acquired	2023-04-17	Common Stock (0)	Indirect
2018-04-16	Warrants	$0.32	P	0	Acquired	2023-04-17	Common Stock (0)	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants	$1.50	2022-06-14	Common Stock (2000000)	2000000	Indirect
Warrants	$1.50	2022-06-14	Common Stock (0)	2000000	Indirect
Warrants	$1.50	2022-06-14	Common Stock (0)	2000000	Indirect
Warrants	$0.32	2023-04-17	Common Stock (15937500)	15937500	Direct
Warrant	$0.32	2023-04-17	Common Stock (0)	15937500	Indirect
Warrant	$0.32	2023-04-17	Common Stock (0)	15937500	Indirect

Footnotes

F1: This constitutes the weighted average purchase price. The prices range from $0.30 to $0.351. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: The reported securities are directly owned by Armistice Capital Master Fund, Ltd.

F3: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd.

F4: This constitutes the weighted average purchase price. The prices range from $0.329 to $0.395. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F5: This constitutes the weighted average purchase price. The prices range from $0.393 to $0.492. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F6: These warrants are currently exercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 9.99% beneficial owner of the Common Shares following such exercise.

F7: These warrants are currently excercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 4.99% beneficial owner of the Common Shares following such exercise.

F8: The Series C Convertible Preferred Stock has no expiration date and is convertible at any time at the option of Armistice Capital Master Fund, Ltd., subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from converting the Series C Convertible Preferred Stock into Common Shares if it would be more than a 4.99% beneficial owner of the Common Shares following such conversion.